Browse by regulation1 article · 1 moderate
FDA draft guidance Docket FDA-2025-D-1106
Every DSRV article whose Regulatory Snapshot cites FDA draft guidance Docket FDA-2025-D-1106: the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.
Inspection exposure across the set
- What has FDA cited under FDA draft guidance Docket FDA-2025-D-1106?
- 1 DSRV article cite FDA draft guidance Docket FDA-2025-D-1106. Enforcement cases behind them: FDA draft guidance for industry, Q1 Stability Testing of Drug Substances and Drug Products, published for U.S. comment in June 2025 under Docket FDA-2025-D-1106, consolidating the ICH Q1A-F and Q5C stability guidelines. Inspection exposure across them: 1 moderate.
- What does DSRV recommend for FDA draft guidance Docket FDA-2025-D-1106?
- From the newest article (Your Stability Program Was Built for a Guideline Stack FDA Is Replacing): The right response to a draft-not-for-implementation label is a controlled gap assessment against Sections 3, 7, 13, and 15, not blind SOP revision, because teams that map the direction of travel early avoid retrofitting under pressure at final regional implementation. DSRV is decision support, not legal advice; verify against the official source each article names.
In brief
Address this risk
Pressure-test your evidence before an inspector reads it
Bring the document that has to hold up under FDA draft guidance Docket FDA-2025-D-1106. DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.
Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.